One year outcomes of eyes with polypoidal choroidal vasculopathy with ≥20/40 visual acuity treated with anti-vascular endothelial growth factor agents

PURPOSE: To report the 12 months outcomes of treatment naïve polypoidal choroidal vasculopathy (PCV) in patients with ≥20/40 Snellen's best-corrected visual acuity (BCVA). METHODS: This was a retrospective study including eyes treated with monotherapy of anti-vascular endothelial growth factors...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Sumit R., Goud, Nallamasa R., Goud, Abhilash, Sahoo, Niroj K., Narayanan, Raja, Chhablani, Jay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8982935/
https://www.ncbi.nlm.nih.gov/pubmed/35391819
http://dx.doi.org/10.4103/1319-4534.337862

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8982935/
https://www.ncbi.nlm.nih.gov/pubmed/35391819
http://dx.doi.org/10.4103/1319-4534.337862

Ejemplares similares